Research programme: AMP kinase stimulants - Rigel Pharmaceuticals
Latest Information Update: 29 Apr 2016
At a glance
- Originator Rigel Pharmaceuticals
- Class Small molecules
- Mechanism of Action AMP activated protein kinase stimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer; Musculoskeletal disorders
- No development reported Atherosclerosis; Type 2 diabetes mellitus